Abstract:Modified electroconvulsive therapy (MECT) is an effective treatment for mood and psychiatric disorders and provides rapid and significant improvements in severe symptoms of several mental health conditions. We attempted to compare the urinary proteome of each depressive patient before and after electroconvulsive therapy. The common biological processes enriched by differential proteins through GO analysis with most patients mainly included cell adhesion (9/9 patients), immune response (7/9), axon guidance (7/9), and oxidation stress (7/9). Moreover, the common biological pathways identified by Ingenuity Pathway Analysis software showed that acute phase response signaling (7/9 patients), NRF2-mediated oxidative stress response (7/9), synaptogenesis signaling pathway (5/9), and ephrin B signaling (5/9) were all upregulated among each patient and were involved in promoting synaptic plasticity and neuroplasticity. Common biological processes and pathways in urine were reported to be related to the mechanism of MECT in the treatment of mental illnesses. In addition, the common differential proteins CSPG4, CBG, APP, NCAM1, and ARSA were suspected to be related to memory loss, memory damage, and memory formation, which might be the effects of MECT.### Competing Interest StatementThe authors have declared no competing interest.### Clinical TrialChiCTR2200059053### Funding StatementSTI2030-Major Projects(No. 2021ZD0200600)and Beijing Hospitals Authority Youth Programme(No. QML20211902）.### Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the STI2030-Major project (2021ZD0200600) admitted by the Anding Hospital Ethics Review Committee.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript

Predicting the efficacy of escitalopram in the treatment of depression through urinary proteome

Label-Free Liquid Chromatography–Mass Spectrometry Proteomic Analysis of the Urinary Proteome for Measuring the Escitalopram Treatment Response from Major Depressive Disorder

Identification of early candidate urine biomarkers for measure Escitalopram treatment response from major depressive disorder

Predicting Escitalopram Monotherapy Response in Depression: the Role of Anterior Cingulate Cortex

Comparison of the Urinary Proteome in Depressed Patients Before and after Modified Electroconvulsive Therapy

A genome-wide association study of escitalopram treatment outcomes in patients with major depressive disorder

Predicting Antidepressant Citalopram Treatment Response via Changes in Brain Functional Connectivity After Acute Intravenous Challenge

CYP2C19 Genotyping May Provide a Better Treatment Strategy when Administering Escitalopram in Chinese Population

Metabolomics Signatures of serotonin reuptake inhibitor (Escitalopram), serotonin norepinephrine reuptake inhibitor (Duloxetine) and Cognitive Behavior Therapy on Key Neurotransmitter Pathways in Major Depressive Disorder

Development and Validation of UHPLC-MS/MS Method for Simultaneous Quantification of Escitalopram and Its Major Metabolites in Human Plasma and Its Application in Depressed Patients.

Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression

Pilot Study of Genome-Wide DNA Methylation and Gene Expression for Treatment Response to Escitalopram in Panic Disorder.

Kynurenic acid is a potential overlapped biomarker between diagnosis and treatment response for depression from metabolome analysis

Response Trajectories During Escitalopram Treatment of Patients with Major Depressive Disorder

Characterization of gut microbiome in mice model of depression with divergent response to escitalopram treatment.

DNA methylation of serotonin genes as predictive biomarkers of antidepressant treatment response

Predictors of 4-week antidepressant outcome in patients with first-episode major depressive disorder: An ROC curve analysis

Effects of escitalopram on synaptic density in the healthy human brain: a randomized controlled trial

Urine proteomic analysis of patients with schizophrenia

Acute Neurofunctional Effects of Escitalopram in Pediatric Anxiety: A Double-Blind, Placebo-Controlled Trial

Efficacy of Escitalopram Monotherapy in the Treatment of Major Depressive Disorder